RHA Collection (Teoxane)
Resilient HA filler designed for dynamic facial wrinkles
About This Treatment
The RHA Collection by Teoxane is the world's first FDA-approved HA filler specifically designed for dynamic wrinkles. Using proprietary "Preserved Network Technology," it maintains a structure closely mimicking natural hyaluronic acid. Unlike conventional HA products, RHA fillers stretch and move with facial expressions while maintaining structural support.
In 2025, the anesthetic was switched from lidocaine to mepivacaine—the first major anesthetic innovation in HA fillers in nearly two decades. The collection includes RHA 2 (moderate wrinkles), RHA 3 (deep wrinkles), RHA 4 (volume), and RHA Redensity (delicate areas).
Mechanism of Action
Preserved Network Technology minimizes chemical cross-linking while maintaining natural HA molecular structure. This achieves optimal balance between elasticity (G') and viscosity (G"), allowing the filler to move naturally with facial muscles while maintaining structural support.
Indications
Expected Results
Immediate results lasting 15-18 months. Final results stabilize 2-4 weeks post-treatment. 70-85% improvement in dynamic wrinkles. Mepivacaine formulation significantly improves injection comfort compared to lidocaine.
Clinical Evidence
Risks & Side Effects
Injection site redness, swelling, tenderness (resolves in 1-3 days). Rare bruising or nodule formation. Very rare vascular occlusion (reversible with hyaluronidase). Check for mepivacaine allergy history.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition